Extract from the Register of European Patents

EP About this file: EP1265911

EP1265911 - 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.03.2009
Database last updated on 26.03.2026
Most recent event   Tooltip22.01.2021Change - lapse in a contracting statepublished on 24.02.2021  [2021/08]
Applicant(s)For all designated states
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
The National Institute of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325
Rockville, MD 20852 / US
[2008/21]
Former [2002/51]For all designated states
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
c/o National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804 / US
Inventor(s)01 / KIM, Hyun, K.
6308 Marywood Road
Bethesda, MD 20817 / US
02 / BLYE, Richard, P.
7352 Mink Hollow Road
Highland, MD 20777 / US
03 / RAO, Pemmaraju, N.
4307 North Westberry Drive
San Antonio, TX 78228 / US
04 / CESSAC, James, W.
11815 Vance Jackson, 602
San Antonio, TX 78230 / US
05 / ACOSTA, Carmie, K.
318 Addax
San Antonio, TX 78213 / US
06 / SIMMONS, Anne, Marie
2032 West Mistletoe
San Antonio, TX 78201 / US
 [2002/51]
Representative(s)Woods, Geoffrey Corlett
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
[N/P]
Former [2002/51]Woods, Geoffrey Corlett
J.A. KEMP & CO. Gray's Inn 14 South Square
London WC1R 5JJ / GB
Application number, filing date01918812.716.03.2001
[2002/51]
WO2001US08681
Priority number, dateUS2000052685517.03.2000         Original published format: US 526855
[2002/51]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO0174840
Date:11.10.2001
Language:EN
[2001/41]
Type: A2 Application without search report 
No.:EP1265911
Date:18.12.2002
Language:EN
The application published by WIPO in one of the EPO official languages on 11.10.2001 takes the place of the publication of the European patent application.
[2002/51]
Type: B1 Patent specification 
No.:EP1265911
Date:21.05.2008
Language:EN
[2008/21]
Search report(s)International search report - published on:EP02.05.2002
ClassificationIPC:C07J41/00, A61K31/57, C07J31/00, C07J7/00, C07J5/00, C07J9/00, A61K31/575, A61P5/36
[2002/51]
CPC:
C07J43/003 (EP); A61P15/00 (EP); A61P15/04 (EP);
A61P15/18 (EP); A61P35/00 (EP); A61P5/24 (EP);
A61P5/36 (EP); A61P5/44 (EP); C07J31/006 (EP);
C07J41/0016 (EP); C07J41/0083 (EP); C07J5/0053 (EP);
C07J7/0045 (EP); C07J7/0085 (EP); C07J9/00 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2002/51]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:17-ALPHA-SUBSTITUIERTE-11-BETA-SUBSTITUIERTE-4-ARYL UND 21-SUBSTITUIERTE 19-NORPREGNADIENEDIONE MIT ANTIGESTAGENER AKTIVITÄT[2002/51]
English:17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS[2002/51]
French:MODIFICATION STRUCTURALE DE 19-NORPROGESTERONE I: 17-ALPHA-SUBSTITUE-11-BETA-SUBSTITUE-4-ARYLE ET 21-SUBSTITUE 19-NORPREGNADIENEDIONE EN TANT QUE NOUVEAUX AGENTS ANTIPROGESTATIFS[2002/51]
Entry into regional phase09.10.2002National basic fee paid 
09.10.2002Designation fee(s) paid 
09.10.2002Examination fee paid 
Examination procedure15.10.2001Request for preliminary examination filed
International Preliminary Examining Authority: EP
09.10.2002Amendment by applicant (claims and/or description)
09.10.2002Examination requested  [2002/51]
16.08.2004Despatch of a communication from the examining division (Time limit: M06)
20.06.2005Reply to a communication from the examining division
15.03.2007Date of oral proceedings
20.04.2007Communication of intention to grant the patent
09.10.2007Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
13.11.2007Fee for grant paid
13.11.2007Fee for publishing/printing paid
Divisional application(s)EP08009259.6  / EP2033965
EP10010646.7  / EP2348031
EP10010647.5  / EP2348030
Opposition(s)24.02.2009No opposition filed within time limit [2009/18]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
13.11.2007Request for further processing filed
13.11.2007Full payment received (date of receipt of payment)
Request granted
13.12.2007Decision despatched
20.06.2005Request for further processing filed
20.06.2005Full payment received (date of receipt of payment)
Request granted
08.08.2005Decision despatched
Fees paidRenewal fee
24.03.2003Renewal fee patent year 03
22.03.2004Renewal fee patent year 04
22.03.2005Renewal fee patent year 05
29.03.2006Renewal fee patent year 06
28.03.2007Renewal fee patent year 07
27.03.2008Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Former [2010/23]deleted
Former [2009/07]SE21.08.2008
Cited inInternational search[XT]   RAO P N ET AL: "11beta-Substituted 13beta-ethyl gonane derivatives exhibit reversal of antiprogestational activity", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 63, no. 1, 1998, pages 50 - 57, XP004103060, ISSN: 0039-128X [X] 1-3,6-8,10,49-60 * page 51, figure 1, compound CDB-2914; page 52, figure 2, compounds 12a and 13a; page 56; table 1 * [T] 1-3,6-8,49-60

DOI:   http://dx.doi.org/10.1016/S0039-128X(97)00119-0
 [X]   RAO P N ET AL: "New 11beta-aryl-substituted steroids exhibit both progestational and antiprogestational activity", STEROIDS: STRUCTURE, FUNCTION, AND REGULATION,US,ELSEVIER SCIENCE PUBLISHERS, NEW YORK, NY, vol. 63, no. 10, 1 October 1998 (1998-10-01), pages 523 - 530, XP004140834, ISSN: 0039-128X [X] 1-3,6-8,10,49-60 * page 528; table 2 *

DOI:   http://dx.doi.org/10.1016/S0039-128X(98)00060-9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.